With the advent of drug-eluting stents (DES), the clinical outcomes of percutaneous coronary intervention (PCI) improved dramatically. In particular, second-generation DES are characterized by thinner stent struts and improved new polymer coating, which facilitate vessel healing relative to first-generation DES. However, stent-related adverse events such as very late stent thrombosis (VLST) occur in the chronic phase even with second-generation DES. Local inflammation induced by stent struts combined with persistence of anti-proliferative drug remains an especially important nidus of late stent failure. To overcome those remaining issues, bioresorbable scaffolds (BRS) were introduced with the hope of achieving complete uncaging of the vessel wall following short-term scaffolding.